

Veriox®DECON Animal is intended for emergency response to a known or suspected chemical or biological agents exposure to neutralize, destroy and/or remove the threat.

### **DECONTAMINATES:**

- Chemical Agents
- Biological Agents
- Fentanvl

### **ALSO KILLS:**

- Spores (including Anthrax)
- Bacteria (including Antibotic resistant strains)
- Viruses (including SARS-CoV-2)

# TRAINING KIT CONTAINS: 16oz bottle and 3 microfiber wipes

**PRODUCT DESCRIPTION:** Veriox®DECON for Animals is intended for emergency response to a known or suspected chemical or biological agents exposure to neutralize, destroy and/or remove the threat.

**WARNING:** External use only. Not for injection or ophthalmic use.

**IF IN EYES:** Rinse continuously with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing. If eye irritation persists, get medical advice/attention.

STORAGE: Store between 34-86 °F (2-30 °C)

**DISPOSAL:** In accordance with applicable regional, national and local laws and regulations.





- 1. Open the clear plastic container.
- 2. Open bottle and pour liquid on enclosed microfiber wipes.

### Can Pour Directly on Affected Area.

- 3. Clean exposed fur and skin with wipes. No rinse required.
- 4. Discard bottle and wipes after use.






FOR MORE INFORMATION CONTACT:
Michael Voss, Chief Executive Officer
+1-210-919-8059

mike.voss@armisbiopharma.com








## Animal efficacy testing performed by US-MRICD

- Procedure (guinea pigs)
- Expose skin to VX, wait 2 min
- 10 swipes with decontaminant
- Evaluate lethality at 24 hr
- Results: Veriox® outperforms
- LD50 Ratio: 1.8, LD10 Ratio: 1.4

Outperformance later verified with second study



Koplovitz, I., et al.~``Evaluation of Veriox @ as a Skin Decontamination Product after Dermal Exposure to the Nerve Agent VX"; USAMRICD-TR-16-06; Sept. 2016 after Dermal Exposure to the Nerve Agent VX"; USAMRICD-TR-16-06; Sept. 2016 after Dermal Exposure to the Nerve Agent VX"; USAMRICD-TR-16-06; Sept. 2016 after Dermal Exposure to the Nerve Agent VX"; USAMRICD-TR-16-06; Sept. 2016 after Dermal Exposure to the Nerve Agent VX"; USAMRICD-TR-16-06; Sept. 2016 after Dermal Exposure to the Nerve Agent VX"; USAMRICD-TR-16-06; Sept. 2016 after Dermal Exposure to the Nerve Agent VX is a sept. 2016 after D



FOR MORE INFORMATION CONTACT:

Michael Voss, *Chief Executive Officer* +1-210-919-8059

mike.voss@armisbiopharma.com

